BBIO vs PG · rev $221.9M vs P/E 25, rev $84.28B
BridgeBio Pharma Inc (BBIO) versus Procter & Gamble Company (PG) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Procter & Gamble Company (PG) is a household & personal products company listed on US. It is led by Jon Moeller.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported PG revenue for 2025-06-30 was $84.28B. Net income was $15.97B. PG currently screens at market cap $373.53B and trailing P/E 25.3.
BBIO currently screens at market cap $13.24B. PG currently screens at market cap $373.53B and trailing P/E 25.3.
Not investment advice. Open the BBIO and PG stock pages for the full models.
Not investment advice.